This serological test, called ‘ELISA Kit’, can detect antibodies and will show if a person has been in contact with the SARS-CoV-2 virus and if
their immune system has reacted in such a way that they have consequently become immune to the virus.
The new technology, presented at the CSIC headquarters, has been validated by the
Immunology services of the La Princesa and La Paz hospitals -both in Madrid- and is going to be
manufactured by a Spanish company (Immunostep), so that it can be made available to hospitals in approximately one and a half months.
According to the scientists who have participated in its development, the ‘ELISA Kit’ hopes to become
one of the most reliable technologies for carrying out serological tests among the population, given that it has been based on procedures that are already being carried out on a regular basis in many hospitals and specialised laboratories.
Serological tests, as CSIC officials pointed out during the presentation of the ELISA kit, are
essential to determine who has contributed to the virus and whether they have become immune to the virus. The success of this new technology lies, above all, in the
high percentage of reliability in determining whether the immune system has reacted to SARS-CoV-2. A factor that, up until now, was very low.
The CSIC’s battle against coronavirus
Rosa María Menéndez López, president of the CSIC, during the presentation of the ‘ELISA Kit’, on 7 July. Photo: twitter.com/CSIC
Four CSIC research groups have worked against the clock during the confinement period to develop this new type of serological test. Together with these researchers,
many other researchers are also working on different projects to learn more about the components of the new virus and find solutions in order to develop a vaccine.
Spanish National Research Council has been working since March on some 50 projects related to Covid-19. Thanks to the 4.5 million euros allocated by the Ministry of Science to Covid-19 research, the CSIC is developing projects to clone the virus in order to
genetically manipulate it, attenuate its virulence and obtain vaccines;
rapid early diagnosis techniques; key genomic analyses to find out how the virus spreads;
air analysis; and
analysing general population data to find out more about how the
virus circulates, among others.
11,000 people work at the CSIC, the epicentre of Spanish scientific research, in
120 centres throughout Spain.
You may be interested: